跳至主要内容
临床试验/NCT01584726
NCT01584726Unknown不适用

Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)

Hamad Medical Corporation2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2012年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
400
试验地点
2
主要终点
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?

研究概览

简要总结

The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

详细描述

the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency

follow asthma severity score and length of stay

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
2 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Pediatric asthma patients with moderate to severe exacerbation

排除标准

  • Known allergy to magnesium sulfate
  • History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
  • Use of oral steroid medication within 72 hours of presentation
  • Radiographic evidence of pneumonia at presentation
  • Administration of intravenous magnesium sulfate prior to study enrollment

研究组 & 干预措施

magnesium sulfate arm

Other

magnesium sulfate with standard therapy

干预措施: Magnesium Sulfate (Drug)

结局指标

主要结局

Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?

时间窗: 36 months

次要结局

  • • Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo(36 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Nebulized Magnesium Sulfate in Children With... | 临床试验